Slowing Disability in MS

This episode of The BioReport explores Immunic Therapeutics' experimental oral therapy, Vitofudimus Calcium (also referred to as flutofludimus calcium), for multiple sclerosis (MS). Host Daniel Levine interviews CEO Daniel Vitt, who explains how the drug’s dual mechanism—targeting both inflammation via DHODH inhibition and neurodegeneration through Nrf1 activation—could address a major unmet need in MS treatment: the silent, progressive loss of neurological function that current therapies fail to halt. The discussion highlights the drug’s strong safety profile, promising Phase 2 results showing significant reductions in brain lesions and early signs of neuroprotection, and its potential to become a first-line oral option, especially for patients switching from anti-CD20 therapies or those seeking safer alternatives. The company is advancing into Phase III trials in relapsing MS and planning a Phase III in primary progressive MS, with data expected by 2030. A major $400 million financing round, structured with tranches tied to clinical milestones, underscores investor confidence and supports both development and commercial launch planning. Vitt emphasizes the company’s strategy to build its own commercial infrastructure rather than pursue early acquisition, positioning Immunic as a potential leader in next-generation MS therapy. Key takeaways include: (1) Vitofudimus Calcium uniquely targets both inflammation and neurodegeneration, addressing the core limitation of current MS drugs; (2) Its favorable safety profile—lacking common side effects like hair loss and GI issues—could improve patient adherence and clinician adoption; (3) The drug may serve as a safe, effective switch option for patients on anti-CD20 therapies who face infection risks; (4) Phase III data readouts in 2027 (relapsing MS) and 2030 (progressive MS) will be pivotal for regulatory approval and market entry; (5) Immunic’s strategic financing and commercial readiness signal a shift from R&D-stage to commercial-stage biotech. The episode conveys cautious optimism about the therapy’s potential to transform MS treatment, particularly for progressive forms where options are extremely limited.